Thrombopoiesis stimulating recombinant fusion protein that binds to the thrombopoietin (TPO) receptor (mpl). Peptibody structure consists of 2 disulfide-bonded human IgG1 Fc domains each covalently linked to a peptide containing 2 TPO receptor binding sequences. Has no sequence homology to endogenous TPO. Mol wt 60 kDa. Prepn by cloning and expression in E. coli: C.-F. Liu et al., WO 0024770; eidem, US 6835809 (2000, 2004 both to Amgen). Stimulation of megakaryopoiesis in vitro by Mpl binding: V. C. Broudy, N. L. Lin, Cytokine 25, 52 (2004) DOI PubMed. Clinical pharmacodynamics and pharmacokinetics: Y. Kumagai et al., J. Clin. Pharmacol. 47, 1489 (2007) DOI PubMed. Clinical impact on quality of life in immune thrombocytopenic purpura (ITP): S. D. Mathias et al., Clin. Ther. 29, 950 (2007) DOI PubMed; on durable platelet response in chronic ITP: D. J. Kuter et al., Lancet 371, 395 (2008) DOI PubMed. Review of development and clinical experience in thrombocytopenia in ITP and myelodyplastic syndromes: R. V. Tiu, M. A. Sekeres, Expert Opin. Biol. Ther. 8, 1021-1030 (2008) DOI PubMed.
Antithrombocytopenic.
Antithrombocytopenic